Boston Scientific Corporation (BSX) Position Increased by IBM Retirement Fund

IBM Retirement Fund boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 122.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,525 shares of the medical equipment provider’s stock after buying an additional 18,483 shares during the period. IBM Retirement Fund’s holdings in Boston Scientific Corporation were worth $1,038,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BSX. NGAM Advisors L.P. raised its stake in shares of Boston Scientific Corporation by 12.4% in the second quarter. NGAM Advisors L.P. now owns 49,840 shares of the medical equipment provider’s stock valued at $1,382,000 after buying an additional 5,513 shares in the last quarter. Sumitomo Life Insurance Co. raised its stake in shares of Boston Scientific Corporation by 12.6% in the second quarter. Sumitomo Life Insurance Co. now owns 134,584 shares of the medical equipment provider’s stock valued at $3,731,000 after buying an additional 15,031 shares in the last quarter. Private Wealth Partners LLC raised its stake in shares of Boston Scientific Corporation by 0.4% in the second quarter. Private Wealth Partners LLC now owns 208,051 shares of the medical equipment provider’s stock valued at $5,767,000 after buying an additional 785 shares in the last quarter. Moody Lynn & Lieberson LLC bought a new stake in Boston Scientific Corporation during the second quarter worth about $3,715,000. Finally, Shell Asset Management Co. raised its stake in Boston Scientific Corporation by 4.2% in the second quarter. Shell Asset Management Co. now owns 161,181 shares of the medical equipment provider’s stock worth $4,468,000 after buying an additional 6,539 shares during the period. Institutional investors own 91.62% of the company’s stock.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.94% during trading on Friday, hitting $26.89. The stock had a trading volume of 5,850,175 shares. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51. The stock has a market capitalization of $36.90 billion, a price-to-earnings ratio of 48.10 and a beta of 1.09. The stock’s 50 day moving average is $27.16 and its 200 day moving average is $26.15.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the business earned $0.27 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities research analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Boston Scientific Corporation (BSX) Position Increased by IBM Retirement Fund” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.com-unik.info/2017/08/19/ibm-retirement-fund-acquires-18483-shares-of-boston-scientific-corporation-bsx-updated-updated.html.

A number of research firms have recently issued reports on BSX. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. UBS AG reiterated a “buy” rating and issued a $31.00 target price (up previously from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. BidaskClub lowered Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Finally, BMO Capital Markets restated a “buy” rating and set a $30.00 price objective on shares of Boston Scientific Corporation in a research note on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.06.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $27.25, for a total transaction of $422,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David A. Pierce sold 2,972 shares of the company’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $27.70, for a total transaction of $82,324.40. Following the sale, the senior vice president now owns 28,572 shares of the company’s stock, valued at approximately $791,444.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 207,625 shares of company stock worth $5,686,383. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit